How to Leverage Digital Technologies to Achieve Multi-Stakeholder Collaboration in Clinical Trials: A Sponsor-Focused Perspective
Modern clinical research is characterized by multi-stakeholder involvement. A successful clinical trial is never a one-man show; in-depth collaboration among multiple parties is essential to ensure the smooth and compliant advancement of the project. However, how to strengthen communication and achieve efficient multi-party coordination has posed significant challenges for many sponsors.
In the first module, we explored how to break down data silos and achieve interoperability of clinical trial data. Once data integration across internal and external hospital systems is achieved, personnel responsibilities and workflows inevitably evolve. How can traditional roles, such as Clinical Research Associates (CRAs) and Data Managers (DMs), adapt to the era of digital clinical trials? How can innovations in quality systems drive a qualitative transformation throughout the entire clinical trial process? How can sponsors maximize benefits amidst the wave of digital clinical development? Furthermore, how should all stakeholders effectively fulfill their respective roles, leverage interoperable data, and achieve efficient multi-role collaboration?
To address these questions,2022December 22 (Thursday), 20:00-21:30,VCBeat SelectJoining Forces Once AgainEcoTech, co-hosting a live online public lecture. This course will“How to Leverage Digital Technologies to Achieve Efficient Multi-Role Collaboration in Clinical Research?”[Sponsor Section]》Centered on this theme and incorporating practical case studies, we will address the challenges of multi-party collaboration in clinical trials from the sponsor’s perspective. Subsequently, we will launch the third installment of the course from the perspective of clinical trial sites.
This course also invitesGong Ying, Head of Clinical Development Quality Department, Pfizer ChinaandLiu Yanfei, Director of the Office of the Clinical Trial Institution and Deputy Director of the Clinical Research Center at Fudan University Shanghai Cancer Center, participate together《What Key Steps Should Sponsors Focus on to Achieve Efficient Multi-Party Collaboration in Digital Clinical Research?Thematic Roundtable Discussion: Helping Enterprises Understand the Importance of Multi-Party Collaboration and Reminding Sponsors of Key Considerations
For viewers participating in the live interactive consultation, Yikefu also provided free consulting services on “how to ensure quality control for multi-center, multi-data clinical trials on a single platform,” as well as a special offer of 50% off the first year for the inaugural project of its 3Q XaaS series. During the live stream, there was also an opportunity to receive cash red envelopes!Scan the QR code in the poster below to register for the live stream.：
1. NumbersCurrent Status of Clinical Trial Development
2, Transformation of Work Models Following the Integration of Clinical Data Within and Outside Hospitals
(Roles, Personnel Responsibilities, Workflows, and Quality Systems)
3How to Achieve Efficient Multi-Role Collaboration
4- Case Sharing
5. Looking Ahead
Sponsors of clinical trials, founders or general managers of pharmaceutical companies or CROs
[Recommendation: ★★★★★]
Heads of clinical trial departments at clinical project sponsors, pharmaceutical companies, or CROs
[Recommendation: ★★★★★]
If you belong to the above-mentioned groups or have products in urgent need of commercialization, be sure not to miss this information-packed open lecture.
Founder and CEO of Yikefu Technology; Zhejiang Province Overseas High-Level Talent. Holds a Master’s degree from Zhejiang University, a Master’s degree from West Chester University (USA), and is a PhD Candidate. Member of the Drug Information Association (DIA) and the Society for Clinical Data Management (SCDM). With 20 years of focus on the research, development, application, and promotion of information technology for clinical trials, and over a decade of experience serving sponsors and CROs in Europe and the United States as well as the Chinese market, he possesses extensive industry expertise in the digitalization of clinical trials. During the 12th and 13th Five-Year Plan periods, he successfully completed the planning, construction, and application guidance of GCP technical platforms for new drug clinical evaluation for dozens of large Grade A tertiary hospitals.
With nearly 20 years of experience in managing clinical research projects for oncology drugs and medical devices, as well as overseeing clinical trial institutions, she/he serves as an on-site inspector for clinical trial data verification under the National Medical Products Administration (NMPA). She/He is a Standing Committee Member of the Professional Committee on Clinical Oncology Research Management of the China Anti-Cancer Association (CACA), a Standing Committee Member of the Clinical Trial Professional Committee of the Shanghai Pharmacological Society, and Chair of the IACRN Shanghai-China Chapter.
Head of Clinical Development Quality, Pfizer China. A graduate of Shanghai Medical University with a major in Clinical Medicine, he is a member of the leadership team at Pfizer China’s R&D Center. He is primarily responsible for formulating, maintaining, and overseeing GCP quality strategies and systems for clinical operations in China. With 24 years of experience in the pharmaceutical clinical trial industry, he possesses extensive expertise in clinical operations, including study design, end-to-end trial execution, project management, compliance, inspection readiness, audit preparedness, and the oversight of clinical research institutions across all phases from First-in-Human (FIH) and Phase I to Phase IV trials.
Hangzhou Icov Technology Co., Ltd., originating from the United States and established in China, has dedicated itself to providing professional end-to-end information technology solutions for clinical trials, software services, and one-stop clinical research acceleration services for clinical research centers, sponsors, CROs, and regulatory authorities over 20 years of relentless effort. The company pioneered the full-process digitalization of clinical trials in China, serving more than 60% of registered clinical projects conducted nationwide. It has provided integrated clinical research platform solutions to over 100 Grade A tertiary hospitals and participated in the construction of national major new drug creation clinical evaluation technology platforms under the Ministry of Science and Technology’s 12th and 13th Five-Year Plans at multiple hospitals. The company has earned high recognition from leading domestic Grade A tertiary hospitals such as West China Hospital of Sichuan University, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center, as well as international pharmaceutical companies including IQVIA, Pfizer, and AstraZeneca.
“Artery Open Course” is one of the branded columns under VCBeat’s “VCBeat Select.” Focusing on pain points in healthcare development and systematic solutions, it leverages an online live-streaming platform for knowledge sharing and exchange. By continuously inviting seasoned industry practitioners and experts to co-develop a series of thematic courses, it aims to provide healthcare enterprises with in-depth, high-value practical insights. Artery Open Course: Making knowledge selection simpler.
Scan the QR code below to contact the assistant and schedule a live broadcast.
(If already added, please proactively ask the assistant)
Watch Replay
Scan the QR code below to watch the replay of the first session.
